Eye Disease
26
2
3
16
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.8%
1 terminated out of 26 trials
94.1%
+7.6% vs benchmark
4%
1 trials in Phase 3/4
6%
1 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (26)
Natural History, Pathogenesis, and Outcome of Ocular Disorders
A Multimodal AI Agent for Ophthalmic Clinical Decision Support
Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma
Virtual Reality and Its Use in Reducing Perioperative Stress in Cataract Surgery
THE ROLE OF HEXAMIDINE DIISETHIONATE (ZAMIDINE®) 1MG/ML 0.6ML EYE DROPS IN THE PROPHYLAXIS OF SURGERY OFTALMIC
Characterization of Potential Biomarkers of Eye Disease and Vision
RPE Characterisation With Transscleral Optical Phase Imaging in Retinal Disorders
Multicenter Neonatal Eye Disease Screening in China
Physicians' Health Study II
Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires
Digital Photography to Evaluate Dry Eye
The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)
CNTF Implants for CNGB3 Achromatopsia
The Effect of Resveratrol Based Nutritional Supplement on Choroidal Thickness
Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood
A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
Analysis of Human Tear Proteins in Children
Pilot Study of Human Tear Proteins